Maintenance doses of aspirin above 100 mg reduce the effectiveness of ticagrelor and should be avoided.
Contra-indicated in patients with a history of intracranial hemorrhage, or active pathological bleeding, and in patients with severe hepatic impairment.
- TRADE NAME: Brilinta (AstraZeneca)
- INDICATIONS: Thrombotic cardiovascular events
- CLASS: Antiplatelet (antithrombotic), Antiplatelet; cyclopentyl triazolo-pyrimidine (CPTP)
- HALF-LIFE: 7 hours
- FDA APPROVAL DATE: 07/20/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Carbamazepine, Clarithromycin, Dexamethasone, Digoxin, Efavirenz, Indinavir, Inotersen, Itraconazole, Ketoconazole, Lovastatin, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifampin, Ritonavir, Saquinavir, Simvastatin, Telithromycin, Venetoclax, Voriconazole
- See adverse reactions attributed to class:
BLEEDING RISK
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 06/14/2025
